Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Day One Biopharmaceuticals Inc (DAWN)

Day One Biopharmaceuticals Inc (DAWN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 813,194
  • Shares Outstanding, K 102,676
  • Annual Sales, $ 131,160 K
  • Annual Income, $ -95,500 K
  • EBIT $ -166 M
  • EBITDA $ -164 M
  • 60-Month Beta -1.27
  • Price/Sales 6.53
  • Price/Cash Flow N/A
  • Price/Book 1.89

Options Overview Details

View History
  • Implied Volatility 147.45% (-28.07%)
  • Historical Volatility 95.02%
  • IV Percentile 69%
  • IV Rank 20.02%
  • IV High 613.84% on 10/23/25
  • IV Low 30.71% on 09/04/25
  • Expected Move (DTE 11) 0.98 (12.34%)
  • Put/Call Vol Ratio 0.54
  • Today's Volume 631
  • Volume Avg (30-Day) 4,276
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 57,001
  • Open Int (30-Day) 51,084
  • Expected Range 6.94 to 8.90

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.18
  • Number of Estimates 5
  • High Estimate -0.15
  • Low Estimate -0.23
  • Prior Year -0.69
  • Growth Rate Est. (year over year) +73.91%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.91 +0.19%
on 12/05/25
10.90 -27.34%
on 11/11/25
-1.22 (-13.35%)
since 11/05/25
3-Month
6.66 +18.83%
on 09/25/25
10.90 -27.34%
on 11/11/25
+0.37 (+4.90%)
since 09/05/25
52-Week
5.64 +40.55%
on 08/06/25
13.92 -43.10%
on 12/09/24
-5.54 (-41.16%)
since 12/05/24

Most Recent Stories

More News
Day One Announces Three Year Follow-Up Data From OJEMDA™ (tovorafenib) Phase 2 FIREFLY-1 Trial at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting

Updated data expands clinically meaningful results available from FIREFLY-1 pivotal trial  77% of patients who entered the treatment-free observation period following OJEMDA treatment remained off...

DAWN : 7.92 (-5.04%)
Day One to Participate in the Piper Sandler 37th Annual Healthcare Conference

BRISBANE, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing...

DAWN : 7.92 (-5.04%)
Day One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening Diseases

Acquisition expands Day One’s portfolio with novel antibody-drug conjugate (ADC) emiltatug ledadotin (Emi-Le) Emi-Le has demonstrated early anti-tumor activity in an ongoing Phase 1 study for adenoid...

DAWN : 7.92 (-5.04%)
Day One Announces New OJEMDA™ (tovorafenib) Data to be Presented in Oral Session at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting

Three-year follow-up data from FIREFLY-1 demonstrates durable responses with evidence of clinical stability off treatment, with the potential for retreatment after progression Treatment-free interval...

DAWN : 7.92 (-5.04%)
Day One Reports Third Quarter 2025 Financial Results and Corporate Progress

Commercial execution delivers best quarter launch-to-date with growth across all dimensions of core business Raising OJEMDA full-year 2025 net product revenue guidance to $145 to $150 million ...

DAWN : 7.92 (-5.04%)
Day One to Report Third Quarter 2025 Financial Results Tuesday, November 4, 2025

BRISBANE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing...

DAWN : 7.92 (-5.04%)
Day One Biopharmaceuticals Reprices Stock Options for Retention

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Day One Biopharmaceuticals...

DAWN : 7.92 (-5.04%)
Day One Reports Second Quarter 2025 Financial Results and Corporate Progress

OJEMDA™  (tovorafenib) net product revenue of $33.6 million in Q2 2025, a 10% quarter-over-quarter increase OJEMDA full-year 2025 net product revenue expected to be $140 to $150 million ...

DAWN : 7.92 (-5.04%)
Day One to Report Second Quarter 2025 Financial Results Tuesday, August 5, 2025

BRISBANE, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing...

DAWN : 7.92 (-5.04%)
Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development

DAWN : 7.92 (-5.04%)

Business Summary

Day One Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It dedicated to developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Day One Biopharmaceuticals Inc. is based in SOUTH SAN FRANCISCO, Calif.

See More

Key Turning Points

3rd Resistance Point 8.89
2nd Resistance Point 8.69
1st Resistance Point 8.31
Last Price 7.92
1st Support Level 7.72
2nd Support Level 7.52
3rd Support Level 7.14

See More

52-Week High 13.92
Fibonacci 61.8% 10.76
Fibonacci 50% 9.78
Fibonacci 38.2% 8.80
Last Price 7.92
52-Week Low 5.64

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar